Lexaria Bioscience (LEXX) Share-based Compensation (2010 - 2026)
Lexaria Bioscience (LEXX) posted Share-based Compensation of $92944.0 for Q2 2026, up 24.1% sequentially from $74895.0 in Q1 2026, and down 81.36% YoY from $498642.0 in Q2 2025.
Lexaria Bioscience (LEXX) Share-based Compensation (2010 - 2026) Analysis & Trends
Lexaria Bioscience has reported Share-based Compensation for 16 years, with the latest figure at $92944.0 in Q2 2026.
- Quarterly Share-based Compensation fell 81.36% year-over-year to $92944.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $365458.0 (down 26.71% YoY) and the FY2025 annual result came in at $859494.0, up 74.61% from the prior year.
- Share-based Compensation improved to $92944.0 in Q2 2026 per LEXX's latest filing, from $74895.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $498642.0 in Q2 2025 and troughed at $9634.0 in Q3 2023.
- A 5-year average of $133587.4 and a median of $94727.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation slumped 95.86% in 2023, then soared 901.76% in 2024.
- Over 5 years, Share-based Compensation stood at $68776.0 in 2022, then slipped by 21.55% to $53953.0 in 2023, then soared by 84.26% to $99415.0 in 2024, then slipped by 24.66% to $74895.0 in 2025, then grew by 24.1% to $92944.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $92944.0, $74895.0, and $74895.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | - |
| 10 | Lexaria Bioscience | 10.31 Mn | 6.70 Mn | - | 92,944.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 92,944.00 |
| May 31, 2026 | 92,944.00 |
| Feb 28, 2026 | 74,895.00 |
| Feb 28, 2026 | 74,895.00 |
| Nov 30, 2025 | 74,895.00 |
| Nov 30, 2025 | 74,895.00 |
| Aug 31, 2025 | 122,724.00 |
| Aug 31, 2025 | 122,724.00 |
| May 31, 2025 | 498,642.00 |
| May 31, 2025 | 498,642.00 |
| Feb 28, 2025 | 167,219.00 |
| Feb 28, 2025 | 167,219.00 |
| Nov 30, 2024 | 99,415.00 |
| Nov 30, 2024 | 99,415.00 |
| Aug 31, 2024 | 96,510.00 |
| Aug 31, 2024 | 96,510.00 |
| May 31, 2024 | 341,773.00 |
| May 31, 2024 | 341,773.00 |
| Nov 30, 2023 | 53,953.00 |
| Nov 30, 2023 | 53,953.00 |